Oligonucleotides are emerging as a powerful new class of therapeutics that show promise as groundbreaking therapies for previously untreatable conditions. More than 700 oligonucleotide drugs are in the pharmaceutical pipeline with several already at the clinical trial stage.

Oligonucleotide therapies are particularly exciting because their highly targeted nature offers patients novel transformative treatments that previously seemed impossible. However, to make this a reality, we have seen that drug manufacturers first of all have to contend with oligonucleotides’ poor pharmacokinetics and pharmacodynamics.

Issues such as tissue targeting, cellular uptake, tolerability and stability all need to be addressed when designing oligonucleotide therapeutics. Chemical modifications and conjugation to a variety of molecules can help overcome these challenges, with peptide conjugation emerging as a promising approach that we will explore in this whitepaper.

Download our whitepaper to find out about:

• The main types of oligonucleotides used as therapeutics
• The barriers and solutions to using oligonucleotides therapeutically
• The key types of peptides which are used for conjugation
• Examples of oligonucleotide conjugates
• Chemistries involved in conjugation
• The main technologies used in conjugation

To learn more about oligonucleotide delivery and accelerate the manufacturing of the next-generation of vital therapeutics, download the whitepaper now.